CDE Detailed Report

Disease: content
Subdomain Name: Functional Outcomes
CRF: welcome

Displaying 1 - 1 of 1
CDE ID CDE Name Variable Name Definition Short Description Question Text Permissible Values Description Data Type Disease Specific Instructions Disease Specific Reference Population Classification (e.g., Core) Version Number Version Date CRF Name (CRF Module / Guidance) Subdomain Name Domain Name Size Input Restrictions Min Value Max Value Measurement Type External Id Loinc External Id Snomed External Id caDSR External Id CDISC
C21726 Karnofsky modified performance status score KarnModPerfStScore Score identifying current level of functioning favoring the highest level estimate Score identifying current level of functioning favoring the highest level estimat Modified Karnofsky Score 100;90;80;70;60;50;40;30;20;10 I feel normal: No complaints. No evidence of disease;I am able to carry on normal activity, with minor symptoms;I carry on normal activity with effort and some symptoms;I am able to care for myself, but unable to carry on normal activities;I require occasional assistance, but can care for most of my needs;I require considerable assistance and frequent care by others;I am disabled. I require considerable assistance and frequent care by others;I am severely disabled. I am hospitalized, but death is not imminent;I am very sick. I require active supportive care by others;I have fatal processes that are rapidly progressing. I am near death Alphanumeric Karnofsky DA, Burchenal JH, Armistead GC, Southam CM, Bernstein JL, Craver LF, Rhoads CP. Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med.1951;87:477–516, 1951. Adult Supplemental 1.00 2016-06-01 09:59:36.0 Functional Status Karnofsky Score Functional Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

CSV